The use of in vivo zebrafish assays in drug toxicity screening

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 4, 2009, Pages 393-401

  Eimon, Peter M ^a   Rubinstein, Amy L ^a,b  

^a 520 Kell Hall ^*  (United States)

^b Zygogen LLC   (United States)

Author keywords

Cardiotoxicity; Developmental toxicology; Gastrointestinal motility; hERG; Ototoxicity; QT prolongation; Safety pharmacology; Seizure liability; Toxicology; Zebrafish

Indexed keywords

ANTIDEPRESSANT AGENT; ANTISENSE OLIGONUCLEOTIDE; CISAPRIDE; CISPLATIN; CROMAKALIM; DOMOIC ACID; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; ISOPRENALINE; MOXIFLOXACIN; NEOMYCIN; NEUROLEPTIC AGENT; OLANZAPINE; PACLITAXEL; PENTAMIDINE; PENTETRAZOLE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG BLOCKING AGENT; PROPRANOLOL; UNCLASSIFIED DRUG;

APOPTOSIS; ASSAY; BEHAVIOR; CARDIOTOXICITY; DRUG TISSUE LEVEL; DRUG TOXICITY; GASTROINTESTINAL MOTILITY; HUMAN; IN VIVO STUDY; LOCOMOTION; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; QT PROLONGATION; REVIEW; SEIZURE; TOXICITY TESTING; VISUAL SYSTEM; ZEBRA FISH;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS; ZEBRAFISH;

DANIO RERIO;

EID: 67649259218     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902882128     Document Type: Review

References (50)

1. Richards FM, Alderton WK, Kimber GM, et al. Validation of the use of zebrafish larvae in visual safety assessment. J Pharmacol Toxicol Methods 2008;58(1):50-58 •• Examines 27 compounds in an optomotor response assay to assess eye toxicity.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-185 (Pubitemid 36279392)
3. Ho RJ, Chien JY. Drug delivery trends in clinical trials and translational medicine: updated analysis of ClinicalTrials.gov database. J Pharm Sci 2008;1-7 [Published online 30 dec]
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-715
5. Boverhof DR, Zacharewski TR. Toxicogenomics in risk assessment: applications and needs. Toxicol Sci 2006;89(2):352-360 (Pubitemid 43125993)
6. Luhe A, Suter L, Ruepp S, et al. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat Res 2005;575(1-2):102-115
7. Foster WR, Chen SJ, He A, et al. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol Pathol 2007;35(5):621-635 (Pubitemid 47123742)
8. Rotman D. Can Pfizer deliver? Technology Rev 2008 [Published online Feb 2008] Available from: http://www.technologyreview.com/ biomedicine/13462/
9. Goldberg AM. Animals and alternatives: societal expectations and scientific need. Altern Lab Anim 2004;32(6):545-551 (Pubitemid 40321533)
10. Jacobs A. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol Lett 2009;186(1):32-35
11. Coecke S, Ahr H, Blaauboer BJ, et al. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern Lab Anim 2006;34(1):49-84 (Pubitemid 43374071)
12. Harrill AH, Rusyn I. Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin Drug Metab Toxicol 2008;4(11):1379-1389
13. Pugsley MK, Gallacher DJ, Towart R, et al. Methods in safety pharmacology in focus. J Pharmacol Toxicol Methods 2008;58(2):69-71
14. Anonymous. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. In: EEC, editor, Offical Journal of the European Communities L 358. 1986. p. 1-28
15. Borski RJ, Hodson RG. Fish research and the institutional animal care and use committee. ILAR J 2003;44(4):286-294 (Pubitemid 46395239)
16. Fleming A. Zebrafish as an alternative model organism for disease modelling and drug discovery: implications for the 3Rs. NC3Rs: National Centre for the Replacement, Refinement and Reduction of Animals in research 2007
17. Rubinstein AL. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2006;2(2):231-240 (Pubitemid 46372366)
18. Hanson LA, Bass AS, Gintant G, et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006;54(2):116-129 (Pubitemid 44293425)
19. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45 (Pubitemid 36351620)
20. Anonymous. S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. In: FDA, editor, Federal Register. 2005. p. 61133-61134
21. Chico TJ, Ingham PW, Crossman DC. Modeling cardiovascular disease in the zebrafish. Trends Cardiovasc Med 2008;18(4):150-155 (Pubitemid 351794544)
22. Burns CG, Milan DJ, Grande EJ, et al. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat Chem Biol 2005;1(5):263-264 • High-throughput QT prolongation assay utilizing transgenic zebrafish with fluorescent hearts; three compounds assessed.
23. Sandberg E, Tran C, White A, et al. Zebrafish assay for automated detection of drug effects on heart rate and cardiac rhythmicity. Toxicology 2007;240(3):159-160
24. Baker K, Warren KS, Yellen G, Fishman MC. Defective "pacemaker" current (Ih) in a zebrafish mutant with a slow heart rate. Proc Natl Acad Sci USA 1997;94(9):4554-4559
25. Milan DJ, Peterson TA, Ruskin JN, et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003;107(10):1355- 1358 •• One hundred compounds tested in heart rate assay to predict QT prolongation. (Pubitemid 36350731)
26. Langheinrich U, Vacun G, Wagner T. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 2003;193(3):370-382 •• Thirteen compounds tested in heart rate assay to predict QT prolongation. (Pubitemid 37543544)
27. Arnaout R, Ferrer T, Huisken J, et al. Zebrafish model for human long QT syndrome. Proc Natl Acad Sci USA 2007;104(27):11316-11321 • A model for long QT syndrome using a zebrafish KCNH2 mutant. (Pubitemid 47175138)
28. Milan DJ, Jones IL, Ellinor PT, MacRae CA. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am J Physiol Heart Circ Physiol 2006;291(1):H269-73 • Measurement of QT interval in adult zebrafish; four drugs assessed.
29. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005;312(1):316-323 (Pubitemid 40096484)
30. Scholz S, Fischer S, Gundel U, et al. The zebrafish embryo model in environmental risk assessment-applications beyond acute toxicity testing. Environ Sci Pollut Res Int 2008;15(5):394-404
31. Berghmans S, Butler P, Goldsmith P, et al. Zebrafish based assays for the assessment of cardiac, visual and gut function - potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 2008;58(1):59-68 •• Sixteen compounds tested in three zebrafish assays. Compound absorption measured by mass spectrometry for nine of the compounds.
32. Mittelstadt SW, Hemenway CL, Craig MP, Hove JR. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J Pharmacol Toxicol Methods 2008;57(2):100-105 •• Eighteen compounds assessed to compare zebrafish hERG assay to patch clamp assays.
33. Genschow E, Spielmann H, Scholz G, et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 2002;30(2):151-176 (Pubitemid 34534620)
34. Goldsmith P. Modelling eye diseases in zebrafish. Neuroreport 2001;12(13):A73-7 (Pubitemid 32881981)
35. Giacomini NJ, Rose B, Kobayashi K, Guo S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicol Teratol 2006;28(2):245-250
36. Airhart MJ, Lee DH, Wilson TD, et al. Movement disorders and neurochemical changes in zebrafish larvae after bath exposure to fluoxetine (PROZAC). Neurotoxicol Teratol 2007;29(6):652-664 (Pubitemid 350101084)
37. Winter MJ, Redfern WS, Hayfield AJ, et al. Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs. J Pharmacol Toxicol Methods 2008;57(3):176-187 •• Assessment of seizure liability in 25 compounds using a zebrafish locomotor assay.
38. Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005;131(3):759-768 (Pubitemid 40261229)
39. Parng C, Roy NM, Ton C, et al. Neurotoxicity assessment using zebrafish. J Pharmacol Toxicol Methods 2007;55(1):103-112 (Pubitemid 46048678)
40. Ou HC, Raible DW, Rubel EW. Cisplatin-induced hair cell loss in zebrafish (Danio rerio) lateral line. Hear Res 2007;233(1-2):46-53 (Pubitemid 47513398)
41. Ton C, Parng C. The use of zebrafish for assessing ototoxic and otoprotective agents. Hear Res 2005;208(1-2):79-88 (Pubitemid 41427131)
42. Chiu LL, Cunningham LL, Raible DW, et al. Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol 2008;9(2):178-190 •• High-throughput zebrafish screen for ototoxic compounds.
43. ANONYMOUS. Background Review Document: Frog Embryo Teratogenesis Assay - Xenopus (FETAX). In: (NICEATM) NTPNICftEoATM, editor, Research Triangle Park; 2000
44. Carney SA, Prasch AL, Heideman W, Peterson RE. Understanding dioxin developmental toxicity using the zebrafish model. Birth Defects Res A Clin Mol Teratol 2006;76(1):7-18 (Pubitemid 43227673)
45. Sachidanandan C, Yeh JR, Peterson QP, Peterson RT. Identification of a novel retinoid by small molecule screening with zebrafish embryos. PLoS ONE 2008;3(4):e1947 (Pubitemid 351984399)
46. Chapin R, Augustine-Rauch K, Beyer B, et al. State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafish. Birth Defects Res B Dev Reprod Toxicol 2008;83(4):446-456 •• Summary of current thinking around the use of zebrafish for predicting developmental toxicity.
47. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 2008;13(9-10):394-401 • Twelve compounds assessed in zebrafish developmental toxicity assay.
48. Ton C, Lin Y, Willett C. Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res A Clin Mol Teratol 2006;76(7):553-567 (Pubitemid 44343958)
49. Redfern WS, Waldron G, Winter MJ, et al. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring? J Pharmacol Toxicol Methods 2008;58(2):110-117 • Assessment of the potential role of zebrafish in safety toxicology screening.
50. Hartung T, Bremer S, Casati S, et al. A modular approach to the ECVAM principles on test validity. Altern Lab Anim 2004;32(5):467-472 (Pubitemid 40128842)